A randomized control trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia with deep molecular response for at least two years

QR Code

A randomized control trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia with deep molecular response for at least two years

Background: There is much advancement in treatment of chronic myeloid leukemia (CML) since the approval of first tyrosine kinase inhibitor (TKI), imatinib, by US FDA in 2001. One of them is definitely the concept of stopping TKI, starting at the CML patients who have achieved deep molecular resp...

Full description

Bibliographic Details
Main Authors:	Kuan, Jew-Win, Chang, Kian-Meng, Loh, Weng Khean, Phan, Chin Lee, Wong, Shu Ping, Chai, Alvin Jung Mau, Yong, Kar Ying, Voon, Kit Kian, Lim, Soo Min, Toh, See Guan
Format:	Proceeding
Language:	English
Published:	2016
Subjects:	RZ Other systems of medicine
Online Access:	http://ir.unimas.my/id/eprint/12285/ http://ir.unimas.my/id/eprint/12285/1/A%20RANDOMIZED%20CONTROL%20TRIAL%20COMPARING%20PEGINTERFERON-%CE%B1-2a.pdf

Similar Items

Targeted RNAi of the mitogen-activated protein kinase pathway genes in acute myeloid leukemia cells
by: Mohd Hafiz, M.R., et al.
Published: (2013)

Survival rate and prognostic factors of survival among chronic myeloid leukaemia adults after initiation of tyrosine kinase inhibitor therapy in Hospital Ampang, Selangor
by: Ali, Zakiah Bakar
Published: (2024)

Self-assembling tyrosine kinase inhibitors for localised targeted delivery
by: Al-Ameedee, Mohammed
Published: (2017)

Survival analysis in acute myeloid leukemia: A retrospective cohort study and simulation study of small events per independent variable / Law Kian Boon
by: Law , Kian Boon
Published: (2017)

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
by: Elias, Marjanu Hikmah, et al.
Published: (2012)

Concomitant t(8;21) and trisomy 4 in a patient with Acute Myeloid Leukemia (AML)
by: Phan CL,, et al.
Published: (2010)

Imbalanced expression of polycistronic miRNA in acute myeloid leukemia
by: Kotaki, Ryutaro, et al.
Published: (2017)

An apoferritin-based drug delivery system for the tyrosine kinase inhibitor gefitinib
by: Kuruppu, Anchala I., et al.
Published: (2015)

A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study
by: Clark, Richard E., et al.
Published: (2017)

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia
by: Ley, T., et al.
Published: (2013)

EGFR-directed tyrosine kinase inhibitors for non-small cell lung cancer
by: Fatin Nur Elyana Mohd Sidek,, et al.
Published: (2025)

Clinical evaluation and proteomic profiles of acute myeloid leukemia patients, Saudi Arabia
by: Almaiman, Amer Abdulrahman
Published: (2015)

Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)

Proteomics profiling and genomics computational analysis of acute myeloid leukemia / Md. Mirazul Islam
by: Md. Mirazul, Islam
Published: (2017)

Analysis of Madm, a novel adaptor protein that associates with Myeloid Leukemia Factor 1
by: Lim, Raelene
Published: (2003)

Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells
by: Alharbi, Raed A., et al.
Published: (2017)

Benzalhydantoin derivative-based inhibitors of eight receptor tyrosine kinases: synthesis, in-vitro, and in-silico study
by: Muhammad Naufal,, et al.
Published: (2025)

Case series of small cell lung cancer transformation post tyrosine kinase inhibitor failure
by: Chai, C.S., et al.
Published: (2017)

Determination of gene expression of tyrosine kinase receptors (HER family) in FFPE tissue of colorectal adenocarcinoma
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)

Activity of the aurora kinase B inhibitor AZD1152 in acute myeloid leukaemia
by: Grundy, Martin
Published: (2012)

Deciphering S-Phase Protein Kinase 2 (Skp2) Mediated Regulation Of Telomerase Reverse Transcriptase (Tert) In Kasumi-1, T (8;21) Acute Myeloid Leukemia (Aml) Cell Line
by: Rosli, Nur Aliaa Arina
Published: (2023)

Detection of BCR-ABL T315i mutation in imatinib resistant chronic myeloid leukemia patients
by: Mardziah M,, et al.
Published: (2019)

Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy.
by: Abdullah, Maha, et al.
Published: (2009)

Subtractive hybridization identifies stem cell-associated genes in an acute myeloid leukemia with poor prognosis
by: Ngiow, Shin Foong, et al.
Published: (2016)

An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
by: Gutteridge, Eleanor
Published: (2010)

Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
by: Carter, Joanne J., et al.
Published: (2016)

Role of Focal Adhesion Tyrosine Kinases in GPVI-Dependent Platelet Activation and Reactive Oxygen Species Formation
by: Carrim, N., et al.
Published: (2014)

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
by: Yu, Yu, et al.
Published: (2015)

Linifanib – a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator
by: Marlow, Maria, et al.
Published: (2015)

The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets
by: Canobbio, I., et al.
Published: (2015)

Eccentricity of Acute Myeloid Leukemia with NPM1 and FLT3-ITD mutation: a case report
by: Nur Zainura Mohamad,, et al.
Published: (2022)

Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy
by: Young, Christine S., et al.
Published: (2017)

Cytotoxic Effects of Betulinic Acid and its Derivatives on Human Myeloid Leukemia (Hl-60) Cell Line
by: Faujan, Nur Hana
Published: (2008)

Spectroscopic and molecular modeling studies on the interaction of tyrosine kinase inhibitors with human serum albumin / Md. Zahirul Kabir
by: Md. Zahirul , Kabir
Published: (2018)

The proline-rich tyrosine kinase Pyk2 regulates platelet integrin aIIbß3 outside-in signaling
by: Cipolla, L., et al.
Published: (2013)

Resistance mechanisms causing first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment failure
by: Chai, C.S., et al.
Published: (2017)

Detection of PDGFRA mutations at exons 12 and 18 among chronic myeloid leukemia patients treated with imatinib mesylate
by: Razali, Ruzi Hamimi
Published: (2015)

Imatinab mesylate treatment in Chronic Myeloid Leukemia (CML)- understanding the fundamental pharmacokinetic and pharmacogenetic mechanisms for variation in response
by: Ankathil, Ravindran
Published: (2016)

Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca2+-dependent tyrosine kinase Pyk2
by: Canobbio, I., et al.
Published: (2013)

Case Series of Small Cell Lung Cancer Transformation as Resistance Mechanism to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
by: Liam, C, et al.
Published: (2017)